THE DEBATE ON HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN

Menopause is biological aging stage of female organism characterized by the absence of a menstrual period for 12 consecutive months without another identifiable cause. It is a transition that typically occurs between 45 and 55 years of age, with a global average age of approximately 51 years. Although menopause is a physiological ovarian aging, it is frequently accompanied by a broad spectrum of symptoms that may substantially impair overall well-being. They vary by system or functional domain (cardiovascular, genitourinary, gastrointestinal, psychological, skeletal and breast- related) involved, as well as their severity. According to clinical investigation found approximately 45.8 % of total studied population having moderate symptoms and 52.7 % having severe symptoms. Given the high prevalence and clinical burden of moderate to severe symptoms, therapeutic intervention is often required. These symptoms are primarily managed with hormonal replacement therapies. However, correlation with long-term health risks involving cardiovascular, genitourinary, hepatobiliary system pathologies, as well as uterine and breast neoplasms is present.